Kennedy's Controversial Claims: Tylenol's Alleged Autism Link in Pregnant Women

U.S. Health Secretary Robert F. Kennedy Jr. plans to announce claims linking Tylenol use in pregnant women to autism, despite lack of evidence. The announcement has led to a drop in Kenvue's shares. The scientific community remains skeptical, awaiting further evidence and ongoing studies.


Devdiscourse News Desk | Updated: 06-09-2025 01:35 IST | Created: 06-09-2025 01:35 IST
Kennedy's Controversial Claims: Tylenol's Alleged Autism Link in Pregnant Women
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

U.S. Health Secretary Robert F. Kennedy Jr. is set to announce claims connecting Tylenol use during pregnancy to autism, according to The Wall Street Journal. Despite no evidence being provided, the news led to a 14% drop in Kenvue's shares, the company behind Tylenol.

Kennedy's assertions clash with the U.S. Food and Drug Administration and medical groups, who affirm the safety of acetaminophen, Tylenol's active ingredient. The debate intensifies as Kennedy's past comments linking vaccines to autism fuel skepticism about his latest claims.

A broader investigation, the Autism Data Science Initiative, is underway to explore potential autism contributors. Some studies suggest a possible link between acetaminophen use and neurodevelopmental disorders but stress the need for further research. The scientific community awaits definitive evidence on the matter.

Give Feedback